HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $16 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $16 price target.
An expert analyst who follows this company says it's still a good investment and thinks it could be worth $16 per share. This suggests the analyst still believes in the company's plans and work, even though their opinion hasn't changed.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.